Masayuki Sho

Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

Takeo Nomi, Masayuki Sho, Takahiro Akahori et al. · Clinical Cancer Research · 2007 · 897 citations

Medicine, Immunology, Oncology +17

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

Qiang Gao, Xiaoying Wang, Shuang‐Jian Qiu et al. · Clinical Cancer Research · 2009 · 818 citations · Full text

Life Sciences, Immunology, Oncology +17

Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

Yuichiro Ohigashi, Masayuki Sho, Yukishige Yamada et al. · Clinical Cancer Research · 2005 · 792 citations · Full text

Medicine, Oncology, Pathology +17

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda et al. · Journal of Clinical Oncology · 2013 · 633 citations

Medicine, Oncology, Pharmacology +13

Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)

Fuyuhiko Motoi, Tomoo Kosuge, Hideki Ueno et al. · Japanese Journal of Clinical Oncology · 2018 · 534 citations · Full text

Medicine, Oncology, Surgery +15